Remove 2026 Remove Biopharma Remove Networking
article thumbnail

Sandoz mobilises critical medicine production in Europe

European Pharmaceutical Review

Sandoz] has the only major remaining vertically-integrated production network for penicillins in Europe” Penicillins are the leading category of antibiotics worldwide, Sandoz highlighted. Launch of these new facilities help to ensure sustainable access to quality antibiotics and spearhead development of biosimilars, Sandoz noted.

article thumbnail

CPHI Pharma Awards 2023 finalists announced

European Pharmaceutical Review

Award winners will be revealed at a networking reception on the first day of CPHI Barcelona 2023, which is running from 24-26 October. CUBIC CRO Service Dr Ferrer Biopharma: GentleMist Technology IamFluidics B.V.: Are you coming to the CPHI Barcelona 2023?

Pharma 119
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Beyond transparent pricing: decoding the strategies of major PBMs

Clarivate

Express Scripts ClearNetwork (effective from early 2024) Cost-plus pricing model; includes ESI’s 65,000-plus site retail pharmacy network; prescription pricing is based on the lowest of three benchmarks: NADAC, WAC or PAC; Pharmacies receive a flat dispensing fee plus up to 15% markup.

Retail 59
article thumbnail

Pharma’s pain from the Inflation Reduction Act will be felt well beyond the first 10 brands facing price cuts

Clarivate

Starting in 2026, the first ten self-administered Part D drugs in the law’s cross hairs will receive price cuts of 38%-79%. To learn more about how Clarivate helps biopharma innovators navigate a fast-changing market access environment, please visit us our website.

article thumbnail

U.S. market access landscape: A push for control is erasing the boundary between payers and providers in U.S. healthcare

Clarivate

Oak Street has 169 locations across 21 states and expects to nearly double its size to 300 centers by 2026. Lines are blurring between payers and providers More and more, large integrated delivery networks and national payers are battling each other for greater control over patient costs and outcomes.

article thumbnail

What a string of semaglutide biosimilars could mean for Mainland China

Clarivate

However, availability of cost-effective biosimilars of semaglutide starting 2026 is likely to influence patient perception of the drug in a price-sensitive Chinese market, especially for obese patients in the absence of reimbursement for weight loss drugs.

article thumbnail

How retailers and “payviders” are disrupting U.S. healthcare in 2024

Clarivate

But, even without Amedisys, the insurer still has home healthcare company LHC Group, acquired in early 2023, and will leverage a long-term partnership with Walmart plus the nation’s largest network of employed and affiliated physicians through Optum to manage patient health and drive down costs for vulnerable patients.

Retail 52